dpp-4 inhibitors vs. glp-1 agonist Dipeptidyl peptidase-4 inhibitor Cardiovascular effects of the DPP-4

Levy JC, Matthews DR, Hermans MP

Increased postprandial glucagon-like peptide-1 (GLP-1) production after endoscopic gastrointestinal bypass using the Cousin lumen-apposing stent in a porcine model

Other New Stuff: The Genetics of G-Agonists In a seminal study of the genomics of glucose regulation in nearly 500,000 people, specific coding variants of the GLP-1 receptor (GLP1R) were associated with potential GLP-1 drug response

We know these [GLP-1] drugs not only diminish appetite and aid weight loss, but they also likely affect cardiovascular health, improve insulin sensitivity, and thus decrease overall inflammation in the body

Further research is needed to explore the full therapeutic potential and long-term safety of GLP-1RAs across a broader range of metabolic and neurodegenerative disorders